Discontinuation of potent antiretroviral therapy: Predictive value of and impact on CD4 cell counts and HIV RNA levels

AIDS

Volumn 15, Issue 16, 2001, Pages 2101-2108

  Grant, Linda Ahdieh ^a   Silverberg, Michael J ^a   Palacio, Herminia ^b   Minkoff, Howard ^c   Anastos, Kathryn ^d   Young, Mary A ^e   Nowicki, Marek ^f   Kovacs, Andrea ^f   Cohen, Mardge ^g   Muñoz, Alvaro ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^c MAIMONIDES MEDICAL CENTER   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g Jr Hospital of Cook County   (United States)

Author keywords

CD4 cell count; Discontinuation; HIV; Plasma HIV RNA; Potent antiretroviral therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; DETERIORATION; DIAGNOSTIC VALUE; DRUG POTENCY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT ATTITUDE; PREDICTION; PRIORITY JOURNAL; RNA ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0035834475     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200111090-00005     Document Type: Article

References (22)

1. Host factors in HIV disease
2. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
3. Effectiveness of highly active antiretroviral therapy among HIV-1 infected women
4. Confounding by severity of potent antiretroviral therapy usage in a large cohort of HIV-infected women
5. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants
6. Stopping anti-retroviral treatment
7. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
8. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
9. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
10. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
11. Patterns and predictors of antiretroviral switching among a large cohort of HIV-1 infected women: 1994-1999
12. The Women's Interagency HIV Study
13. Retention of women enrolled in a prospective study of HIV infection: Impact of race, unstable housing, and use of HIV therapy
14. Public health service guidelines for the use of anti-retroviral agents in HIV-infected adults and adolescents. 1998, Updated January
15. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued?
16. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
17. Prevalence and predictors of adherence to antiretroviral therapy (ART) among HIV+ women
18. Boosting of HIV-1 specific cellular immune responses in chronically infected persons following treatment interruption
19. Structured treatment interruption in chronically HIV-1-infected patients after long-term viral suppression
20. Immune control of HIV-1 following early treatment of acute infection
21. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
22. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in pregnancy in previously untreated HIV-1-infected patients